Influence of frequency on the surface discharge characteristics of PEEK under positive repetitive square voltage

Autor: Zhuodong Yang, Xuebao Li, Xiangrui Meng, Zhibin Zhao, Pengyu Fu, Bin Zhai, Xiang Cui

Publikováno v: High Voltage (2020)

In this study, the surface discharge current pulses of polyetheretherketone (PEEK) material under positive repetitive square voltage in a nitrogen atmosphere are measured. The influences of different voltage amplitudes and frequencies on the detail p

Externí odkaz: https://doaj.org/article/085aa4cc315e49eb913c9f57ea6a272c

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission

Autor: Olivier Hermine, Denis Caillot, Karine Celli-Lebras, Céline Berthon, Arnaud Pigneux, Emmanuel Raffoux, Sylvie Chevret, Jean-Pierre Marolleau, Oumedaly Reman, Emilie Lemasle, Hervé Dombret, Norbert Vey, Stéphane de Botton, Xavier Thomas, Jean-Yves Cahn, Marc A. Simon, Claude Preudhomme, Norbert Ifrah, Christian Recher, Sylvie Castaigne, Christine Terré

Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, 2017, 35 (11), pp.1223-1230. ⟨10.1200/JCO.2016.70.4551⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2017, 35 (11), pp.1223-1230. ⟨10.1200/JCO.2016.70.4551⟩

Purpose To evaluate the efficacy and safety of a clofarabine-based combination (CLARA) versus conventional high-dose cytarabine (HDAC) as postremission chemotherapy in younger patients with acute myeloid leukemia (AML). Patients and Methods Patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56560a3634aa7e800e79c4d507e88223
https://u-bourgogne.hal.science/hal-01557436

Cytarabine Dose for Acute Myeloid Leukemia

Autor: Bob, Löwenberg, Thomas, Pabst, Edo, Vellenga, Wim, van Putten, Harry C, Schouten, Carlos, Graux, Augustin, Ferrant, Pieter, Sonneveld, Bart J, Biemond, Alois, Gratwohl, Georgine E, de Greef, Leo F, Verdonck, Martijn R, Schaafsma, Michael, Gregor, Matthias, Theobald, Urs, Schanz, Johan, Maertens, Gert J, Ossenkoppele, M, Van Marwijk Kooy

Publikováno v: New England Journal of Medicine, 364(11), 1027-1036. Massachussetts Medical Society
New England journal of medicine, 364(11), 1027-1036. Massachussetts Medical Society
New England Journal of Medicine, 364(11), 1027-1036. MASSACHUSETTS MEDICAL SOCIETY
Lowenberg, B, Pabst, T, Vellenga, E, van Putten, W, Schouten, H C, Graux, C, Ferrant, A, Sonneveld, P, Biemond, B J, Gratwohl, A, de Greef, G E, Verdonck, L F, Schaafsma, M R, Gregor, M, Theobald, M, Schanz, U, Maertens, J & Ossenkoppele, G J 2011, ' Cytarabine Dose for Acute Myeloid Leukemia ', New England Journal of Medicine, vol. 364, no. 11, pp. 1027-1036 . https://doi.org/10.1056/NEJMoa1010222
New England Journal of Medicine, 364(11), 1027-1036. MASSACHUSETTS MEDICAL SOC

Cytarabine (ara-C) is an important drug in the treatment of acute myeloid leukemia (AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface area) is toxic but results in higher rates of relapse-free survival than does the convent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e9cd9b92a79f76d4e77bf13394bd5eb
https://doi.org/10.1056/nejmoa1010222

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.